



# **Abamectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.0 2024/07/06 6029671-00011 Date of first issue: 2020/06/10

#### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Abamectin Formulation

Manufacturer or supplier's details

Company : MSD

Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000

Emergency telephone number : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

#### 2. HAZARDS IDENTIFICATION

**GHS Classification** 

Acute toxicity (Inhalation) : Category 4

Specific target organ toxicity - :

repeated exposure

Category 2 (Central nervous system)

Short-term (acute) aquatic

hazard

Category 1

Long-term (chronic) aquatic

hazard

Category 1

**GHS** label elements

Hazard pictograms :



Signal word : Warning

Hazard statements : H332 Harmful if inhaled.

H373 May cause damage to organs (Central nervous system)

through prolonged or repeated exposure.

H410 Very toxic to aquatic life with long lasting effects.





Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.0 2024/07/06 6029671-00011 Date of first issue: 2020/06/10

Precautionary statements : Prevention:

P260 Do not breathe mist or vapours.

P271 Use only outdoors or in a well-ventilated area.

P273 Avoid release to the environment.

Response:

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/

doctor if you feel unwell.

P314 Get medical advice/ attention if you feel unwell.

P391 Collect spillage.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

#### Other hazards which do not result in classification

None known.

#### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

# Components

Chemical name	CAS-No.	Concentration (% w/w)
abamectin (combination of avermectin B1a and	71751-41-2	>= 1 -< 2.5
avermectin B1b) (ISO)		
2,6-Di-tert-butyl-p-cresol	128-37-0	>= 0.25 -< 2.5

#### 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

If not breathing, give artificial respiration. If breathing is difficult, give oxygen.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse. Flush eyes with water as a precaution.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms : Harmful if inhaled.





Version SDS Number: Date of last issue: 2023/09/30 Revision Date: 3.0 2024/07/06 6029671-00011 Date of first issue: 2020/06/10

and effects, both acute and

delayed

Protection of first-aiders

May cause damage to organs through prolonged or repeated

exposure.

First Aid responders should pay attention to self-protection.

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

5. FIREFIGHTING MEASURES

Suitable extinguishing media Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Avoid release to the environment. **Environmental precautions** 

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-





Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.0 2024/07/06 6029671-00011 Date of first issue: 2020/06/10

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

### 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not breathe mist or vapours.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labelled containers.

Keep tightly closed.

Keep in a cool, well-ventilated place.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

#### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
abamectin (combination of avermectin B1a and avermec- tin B1b) (ISO)	71751-41-2	TWA	15 μg/m3 (OEB 3)	Internal
		Wipe limit	150 µg/100 cm <sup>2</sup>	Internal
2,6-Di-tert-butyl-p-cresol	128-37-0	TWA (Inhalable fraction and vapor)	2 mg/m3	ACGIH

**Engineering measures** : Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.





Version 3.0

Revision Date: 2024/07/06

SDS Number: 6029671-00011

Date of last issue: 2023/09/30 Date of first issue: 2020/06/10

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face con-

tainment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type Hand protection

Particulates type

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the work-

ing place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : liquid

Colour : light yellow

Odour : characteristic

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available



# **Abamectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.0 2024/07/06 6029671-00011 Date of first issue: 2020/06/10

Initial boiling point and boiling :

range

265 °C

Flash point : 213.2 °C

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : 0.90 - 0.91

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : Not applicable

#### 10. STABILITY AND REACTIVITY



# **Abamectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.0 2024/07/06 6029671-00011 Date of first issue: 2020/06/10

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

Conditions to avoid : None known.
Incompatible materials : Oxidizing agents

Hazardous decomposition

products

No hazardous decomposition products are known.

Can react with strong oxidizing agents.

#### 11. TOXICOLOGICAL INFORMATION

Information on likely routes of : Inhalation

exposure

Skin contact Ingestion Eye contact

Acute toxicity
Harmful if inhaled.

**Product:** 

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: 2.3 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

## **Components:**

### abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Acute oral toxicity : LD50 (Rat): 24 mg/kg

LD50 (Mouse): 10 mg/kg

LDLo (Monkey): 24 mg/kg Symptoms: Dilatation of the pupil

Acute inhalation toxicity : LC50 (Rat): 0.023 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rat): 330 mg/kg

LD50 (Rabbit): 2,000 mg/kg

2,6-Di-tert-butyl-p-cresol:

Acute oral toxicity : LD50 (Rat): > 6,000 mg/kg

Method: OECD Test Guideline 401



# **Abamectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.0 2024/07/06 6029671-00011 Date of first issue: 2020/06/10

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

### Skin corrosion/irritation

Not classified based on available information.

### **Components:**

# abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rabbit

Result : No skin irritation

### 2,6-Di-tert-butyl-p-cresol:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Remarks : Based on data from similar materials

# Serious eye damage/eye irritation

Not classified based on available information.

## **Components:**

# abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rabbit

Result : Mild eye irritation

#### 2,6-Di-tert-butyl-p-cresol:

Species : Rabbit

Result : No eye irritation

Method : OECD Test Guideline 405

Remarks : Based on data from similar materials

### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

### Respiratory sensitisation

Not classified based on available information.

### **Components:**

# abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Test Type : Maximisation Test Exposure routes : Skin contact

Result : Not a skin sensitizer.



# **Abamectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.0 2024/07/06 6029671-00011 Date of first issue: 2020/06/10

## 2,6-Di-tert-butyl-p-cresol:

Test Type : Human repeat insult patch test (HRIPT)

Exposure routes : Skin contact Species : Humans Result : negative

## Germ cell mutagenicity

Not classified based on available information.

## **Components:**

## abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster lung cells

Result: negative

Test Type: Alkaline elution assay

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

## 2,6-Di-tert-butyl-p-cresol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Ingestion

Result: negative

## Carcinogenicity

Not classified based on available information.



# **Abamectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.0 2024/07/06 6029671-00011 Date of first issue: 2020/06/10

#### **Components:**

# abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rat
Application Route : Oral
Exposure time : 105 weeks
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 93 weeks
Result : negative

## 2,6-Di-tert-butyl-p-cresol:

Species : Rat
Application Route : Ingestion
Exposure time : 22 Months
Result : negative

### Reproductive toxicity

Not classified based on available information.

#### **Components:**

## abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Effects on fertility : Test Type: Fertility

Species: Rat, male Application Route: Oral Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Early Embryonic Development: NOAEL: 0.12 mg/kg body

weight

Result: Fetotoxicity

Effects on foetal develop- : -

ment

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Oral

General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight Developmental Toxicity: NOAEL: 0.2 mg/kg body weight

Result: Cleft palate

Remarks: Adverse developmental effects were observed

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: LOAEL: 2 mg/kg body weight

Result: Cleft palate, Teratogenic effects, Reduced embryonic

survival



# **Abamectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.0 2024/07/06 6029671-00011 Date of first issue: 2020/06/10

Remarks: Adverse developmental effects were observed

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 1.6 mg/kg body weight

Result: Teratogenic effects

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experi-

ments.

#### 2,6-Di-tert-butyl-p-cresol:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion

Result: negative

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

### **Components:**

## abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Exposure routes : Ingestion

Target Organs : Central nervous system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

### 2,6-Di-tert-butyl-p-cresol:

Assessment : No significant health effects observed in animals at concentra-

tions of 100 mg/kg bw or less.

#### Repeated dose toxicity

#### **Components:**

## abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rat NOAEL : 1.5 mg/kg Application Route : Oral



# **Abamectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.0 2024/07/06 6029671-00011 Date of first issue: 2020/06/10

Exposure time : 24 Months

Target Organs : Central nervous system

Symptoms : Tremors, ataxia

Species : Mouse

NOAEL : 4.0 mg/kg

Application Route : Oral

Exposure time : 24 Months

Target Organs : Central nervous system

Symptoms : Tremors, ataxia

Species : Dog

NOAEL : 0.25 mg/kg
LOAEL : 0.5 mg/kg
Application Route : Oral
Exposure time : 53 Weeks
Target Organs : Central ner

Target Organs : Central nervous system
Symptoms : Tremors, weight loss
Remarks : mortality observed

Species : Monkey
NOAEL : 1.0 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Target Organs : Central nervous system

## 2,6-Di-tert-butyl-p-cresol:

Species: RatNOAEL: 25 mg/kgApplication Route: IngestionExposure time: 22 Months

## **Aspiration toxicity**

Not classified based on available information.

# Experience with human exposure

## **Components:**

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Ingestion : Symptoms: May cause, Tremors, Diarrhoea, central nervous

system effects, Salivation, tearing

#### 12. ECOLOGICAL INFORMATION

### **Ecotoxicity**

### Components:

## abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 μg/l



# **Abamectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.0 2024/07/06 6029671-00011 Date of first issue: 2020/06/10

Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l

Exposure time: 96 h

LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l

Exposure time: 96 h

LC50 (Cyprinus carpio (Carp)): 42 μg/l

Exposure time: 96 h

LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l

Exposure time: 96 h

Toxicity to daphnia and other:

aquatic invertebrates

EC50 (Americamysis): 0.022 µg/l

Exposure time: 96 h

EC50 (Daphnia magna (Water flea)): 0.34 μg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 100

mg/l

Exposure time: 72 h

M-Factor (Acute aquatic tox-

city

10,000

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 0.52 µg/l

Exposure time: 32 d

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0.03 µg/l

Exposure time: 21 d

NOEC (Mysidopsis bahia (opossum shrimp)): 0.0035 µg/l

Exposure time: 28 d

M-Factor (Chronic aquatic

toxicity)

Toxicity to microorganisms

: 10,000

: EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition

2,6-Di-tert-butyl-p-cresol:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 0.57 mg/l

Exposure time: 96 h

Method: Directive 67/548/EEC, Annex V, C.1.

Toxicity to daphnia and other:

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.48 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

: ErC50 (Pseudokirchneriella subcapitata (green algae)): > 0.24

mg/l



# **Abamectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.0 2024/07/06 6029671-00011 Date of first issue: 2020/06/10

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.24

mq/l

1

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox- :

icity

Toxicity to fish (Chronic tox-

icity)

NOEC (Oryzias latipes (Japanese medaka)): 0.053 mg/l

Exposure time: 30 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0.316 mg/l

Exposure time: 21 d

M-Factor (Chronic aquatic : 1

toxicity)

Toxicity to microorganisms

: EC50: > 10,000 mg/l Exposure time: 3 h

Method: OECD Test Guideline 209

## Persistence and degradability

#### **Components:**

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Stability in water : Hydrolysis: 50 %(< 12 h)

2,6-Di-tert-butyl-p-cresol:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 4.5 % Exposure time: 28 d

Method: OECD Test Guideline 301C

#### Bioaccumulative potential

#### **Components:**

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Bioaccumulation : Bioconcentration factor (BCF): 52

Partition coefficient: n-

octanol/water

log Pow: 4

2,6-Di-tert-butyl-p-cresol:

Bioaccumulation : Species: Cyprinus carpio (Carp)

Bioconcentration factor (BCF): 330 - 1,800

Partition coefficient: n- : log Pow: 5.1





# **Abamectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.0 2024/07/06 6029671-00011 Date of first issue: 2020/06/10

# octanol/water

#### Mobility in soil

#### **Components:**

### abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Distribution among environ-

mental compartments

: log Koc: > 3.6

## Other adverse effects

No data available

#### 13. DISPOSAL CONSIDERATIONS

### **Disposal methods**

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

### 14. TRANSPORT INFORMATION

## **International Regulations**

**UNRTDG** 

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

964

(abamectin (combination of avermectin B1a and avermectin

B1b) (ISO), 2,6-Di-tert-butyl-p-cresol)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

**IATA-DGR** 

UN/ID No. : UN 3082

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.

(abamectin (combination of avermectin B1a and avermectin

B1b) (ISO), 2,6-Di-tert-butyl-p-cresol)

Class : 9 Packing group : III

Labels : Miscellaneous

Packing instruction (cargo

aircraft)

Packing instruction (passen: 964

ger aircraft)

Environmentally hazardous : yes

**IMDG-Code** 

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,



# **Abamectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.0 2024/07/06 6029671-00011 Date of first issue: 2020/06/10

N.O.S.

(abamectin (combination of avermectin B1a and avermectin

B1b) (ISO), 2,6-Di-tert-butyl-p-cresol)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

# Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

#### 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Minister of Industry Regulation No. 23/M-IND/PER/4/2013 concerning the Revision of Minister of Industry Regulation No. 87/M-IND/PER/9/2009 concerning Globally Harmonized System of Classification and Labelling of Chemicals.

Regulation of the Minister of Health No. 472 of 1996 on the Safeguarding of Substances Hazardous to Health

Hazardous substances that must be registered : Not applicable

Government Regulation No. 74 of 2001 on the Management of Hazardous and Toxic Substances

Hazardous substances approved for use : Not applicable

Prohibited substances : Not applicable

Restricted substances : Not applicable

Regulation of the Ministry of Trade No. 7 of 2022 on Distribution and Control of Hazardous Materials

Type of hazardous materials subject to distribution and : Not applicable

control, Annex I

Type of hazardous materials subject to distribution and : Not applicable

control, Annex II

The components of this product are reported in the following inventories:

AICS : not determined



# **Abamectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.0 2024/07/06 6029671-00011 Date of first issue: 2020/06/10

DSL : not determined

IECSC : not determined

#### 16. OTHER INFORMATION

Revision Date : 2024/07/06

**Further information** 

Sources of key data used to compile the Safety Data

compile the Safety Data
Sheet

eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Internal technical data, data from raw material SDSs, OECD

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

:

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk, IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China: IMDG - International Maritime Dangerous Goods: IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recom-



# **Abamectin Formulation**

Version Revision Date: SDS Number: Date of last issue: 2023/09/30 3.0 2024/07/06 6029671-00011 Date of first issue: 2020/06/10

mendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ID / EN